Does perioperative immunotherapy reduce the risk of second primary cancers?

Eur J Cancer. 2023 Nov:194:113355. doi: 10.1016/j.ejca.2023.113355. Epub 2023 Sep 25.

Authors

Marco Tagliamento¹, Jordi Remon¹, David Planchard¹, Benjamin Besse²

Affiliations

¹ Department of Cancer Medicine, Gustave Roussy Cancer Campus, Villejuif, France.
² Department of Cancer Medicine, Gustave Roussy Cancer Campus, Villejuif, France. Electronic address: Benjamin.BESSE@gustaveroussy.fr.

PMID: 37837924
DOI: 10.1016/j.ejca.2023.113355

No abstract available

Keywords: Adjuvant; Immune checkpoint inhibitors; Immunoprevention; Immunotherapy; Neoadjuvant; Second primary cancers.

Publication types

Editorial

MeSH terms

Chemotherapy, Adjuvant
Humans
Immunotherapy / adverse effects
Neoadjuvant Therapy
Neoplasms, Second Primary* / prevention & control